JP2025506173A5 - - Google Patents
Info
- Publication number
- JP2025506173A5 JP2025506173A5 JP2024547537A JP2024547537A JP2025506173A5 JP 2025506173 A5 JP2025506173 A5 JP 2025506173A5 JP 2024547537 A JP2024547537 A JP 2024547537A JP 2024547537 A JP2024547537 A JP 2024547537A JP 2025506173 A5 JP2025506173 A5 JP 2025506173A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- agent
- composition according
- amino acid
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309293P | 2022-02-11 | 2022-02-11 | |
| US63/309,293 | 2022-02-11 | ||
| PCT/US2023/062395 WO2023154870A1 (en) | 2022-02-11 | 2023-02-10 | Interleukin-2 muteins for the treatment of autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506173A JP2025506173A (ja) | 2025-03-07 |
| JP2025506173A5 true JP2025506173A5 (https=) | 2026-02-19 |
Family
ID=85476118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547537A Pending JP2025506173A (ja) | 2022-02-11 | 2023-02-10 | 自己免疫疾患の治療のためのインターロイキン－２ムテイン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230390360A1 (https=) |
| EP (1) | EP4475875A1 (https=) |
| JP (1) | JP2025506173A (https=) |
| KR (1) | KR20240148001A (https=) |
| CN (2) | CN119013034A (https=) |
| AU (1) | AU2023219773A1 (https=) |
| CA (1) | CA3243493A1 (https=) |
| MX (1) | MX2024009868A (https=) |
| TW (1) | TW202400218A (https=) |
| WO (1) | WO2023154870A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170510A (es) * | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
-
2023
- 2023-02-10 CA CA3243493A patent/CA3243493A1/en active Pending
- 2023-02-10 KR KR1020247030225A patent/KR20240148001A/ko active Pending
- 2023-02-10 EP EP23709093.1A patent/EP4475875A1/en active Pending
- 2023-02-10 CN CN202380019852.2A patent/CN119013034A/zh active Pending
- 2023-02-10 TW TW112104789A patent/TW202400218A/zh unknown
- 2023-02-10 WO PCT/US2023/062395 patent/WO2023154870A1/en not_active Ceased
- 2023-02-10 AU AU2023219773A patent/AU2023219773A1/en active Pending
- 2023-02-10 MX MX2024009868A patent/MX2024009868A/es unknown
- 2023-02-10 US US18/167,529 patent/US20230390360A1/en active Pending
- 2023-02-10 JP JP2024547537A patent/JP2025506173A/ja active Pending
- 2023-02-10 CN CN202510423645.4A patent/CN120346304A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100483494B1 (ko) | 감마 인터페론에 대한 인간화 항체 | |
| JP4236493B2 (ja) | 癌マーカー用生物合成結合蛋白質 | |
| JP2021074020A (ja) | 安定化された可溶性融合前ｒｓｖ ｆポリペプチド | |
| KR102276157B1 (ko) | 고글리코실화 인간 혈액응고인자 viii 융합 단백질 및 그 제조방법과 용도 | |
| DK2443137T3 (en) | NOVEL chemokine-binding peptides capable of impeding the sequence for immunity, inflammation and cancer | |
| KR20220010478A (ko) | 기도 감염의 치료 또는 예방용 서브유닛 백신 | |
| KR20180027560A (ko) | Rsv에 대한 백신 | |
| CN105531370A (zh) | 治疗靶向特异性vnar结构域与icosl的分离 | |
| JP2025506173A5 (https=) | ||
| CA3165855A1 (en) | Mutant rsv f protein and use thereof | |
| WO2022046730A2 (en) | Bcma chimeric antigen receptors | |
| JP2020529986A (ja) | Ｃｙｓ−ｍａｂのコンジュゲーション方法 | |
| WO2017121330A1 (zh) | 一种单克隆抗体FnAb8及其应用 | |
| CN106336457B (zh) | 识别mage‑a3抗原短肽的t细胞受体 | |
| CN108727486A (zh) | 长效神经生长因子、制备方法及其组合物 | |
| CN114621356A (zh) | 以il18为分子佐剂的带状疱疹亚单位疫苗 | |
| KR102613962B1 (ko) | 코로나바이러스 유래 수용체 결합 도메인 및 뉴클레오캡시드 단백질을 포함하는 융합단백질 및 이의 용도 | |
| CN101451145A (zh) | 基于t细胞表位的结核基因疫苗及其制备方法和应用 | |
| JP2023532760A (ja) | 特異的結合分子 | |
| JP7429462B2 (ja) | Ｓｓｘ２抗原の短いペプチドを識別するｔ細胞受容体 | |
| JP2022502078A5 (https=) | ||
| KR101570453B1 (ko) | 돼지 유행성 설사 바이러스의 재조합 스파이크 1 단백질을 발현하는 재조합 세포 | |
| EP1891088A1 (en) | Process for the purification of il-18 binding protein | |
| WO2024143497A1 (ja) | Ｃｄ１５３を標的とする医薬組成物 | |
| Sjolander et al. | Bacterial Expression Systems Based on a Protein A and Protein G Designed for the Production of Immunogens: Applications to Plasmodium falciparum Malaria Antigens |